Wellington Management Group Portfolio holdings
Wellington Management Group, founded in 1928 by Walter L. Morgan and headquartered in Boston, Massachusetts, is one of the world’s largest independent asset management firms, overseeing trillions in assets for a diverse client base including pension funds, endowments, and mutual fund investors. Renowned for its active management approach, Wellington offers a broad range of investment strategies across equities, fixed income, multi-asset, and alternative investments, emphasizing deep research and long-term partnerships with clients. The firm gained early fame for launching the Wellington Fund, one of the first balanced mutual funds, and has since maintained a reputation for disciplined, collaborative portfolio management. With a global presence and a focus on customized solutions, Wellington remains a trusted name in institutional and retail investing.
Top Buys
| 1 |
Broadcom
AVGO
|
+$2.06B |
| 2 |
Nasdaq
NDAQ
|
+$1.76B |
| 3 |
Wells Fargo
WFC
|
+$1.1B |
| 4 |
Gilead Sciences
GILD
|
+$978M |
| 5 |
Edwards Lifesciences
EW
|
+$964M |
Top Sells
| 1 |
EOG Resources
EOG
|
+$1.82B |
| 2 |
Apple
AAPL
|
+$1.75B |
| 3 |
HCA Healthcare
HCA
|
+$1.51B |
| 4 |
SPDR S&P 500 ETF Trust
SPY
|
+$1.48B |
| 5 |
PNC Financial Services
PNC
|
+$1.29B |
Sector Composition
| 1 | Technology | 23.24% |
| 2 | Healthcare | 19.6% |
| 3 | Financials | 13.95% |
| 4 | Consumer Discretionary | 9.41% |
| 5 | Industrials | 9.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1626
Snowflake
SNOW
$75.6B
| $875K | ﹤0.01% |
7,615
-6,614
| -46% | -$760K |
|
1627
Ligand Pharmaceuticals
LGND
$3.23B
| $870K | ﹤0.01% |
8,688
-5,714
| -40% | -$572K |
|
1628
Keros Therapeutics
KROS
$628M
| $868K | ﹤0.01% |
+14,949
| New | +$868K |
|
|
JNPR
1629
DELISTED
Juniper Networks
JNPR
| $851K | ﹤0.01% |
21,820
+1,283
| +6% | +$50K |
|
1630
Solid Biosciences
SLDB
$399M
| $835K | ﹤0.01% |
119,804
+77,564
| +184% | +$541K |
|
1631
Supernus Pharmaceuticals
SUPN
$2.57B
| $821K | ﹤0.01% |
26,326
-14,350
| -35% | -$447K |
|
1632
Mine Safety
MSA
$6.67B
| $820K | ﹤0.01% |
4,625
-150
| -3% | -$26.6K |
|
1633
BioCryst Pharmaceuticals
BCRX
$1.72B
| $819K | ﹤0.01% |
+107,820
| New | +$819K |
|
1634
Immunovant
IMVT
$2.85B
| $818K | ﹤0.01% |
28,694
-8,235
| -22% | -$235K |
|
1635
Ardelyx
ARDX
$1.59B
| $815K | ﹤0.01% |
118,270
-3,329
| -3% | -$22.9K |
|
1636
Equity Lifestyle Properties
ELS
$11.9B
| $812K | ﹤0.01% |
11,381
-42,391
| -79% | -$3.02M |
|
1637
Arvinas
ARVN
$583M
| $808K | ﹤0.01% |
32,789
+6,330
| +24% | +$156K |
|
1638
iShares Russell 1000 Value ETF
IWD
$63.5B
| $799K | ﹤0.01% |
4,210
+10
| +0.2% | +$1.9K |
|
1639
Western Union
WU
$2.82B
| $787K | ﹤0.01% |
65,957
-2,134
| -3% | -$25.5K |
|
1640
Broadridge
BR
$29.7B
| $776K | ﹤0.01% |
3,610
-110
| -3% | -$23.7K |
|
1641
LiveRamp
RAMP
$1.81B
| $776K | ﹤0.01% |
31,306
+8,133
| +35% | +$202K |
|
1642
Mineralys Therapeutics
MLYS
$2.79B
| $775K | ﹤0.01% |
+63,998
| New | +$775K |
|
1643
Descartes Systems
DSGX
$9.23B
| $775K | ﹤0.01% |
7,519
+347
| +5% | +$35.7K |
|
1644
Celcuity
CELC
$2.65B
| $770K | ﹤0.01% |
+51,611
| New | +$770K |
|
1645
Neurogene
NGNE
$278M
| $767K | ﹤0.01% |
+18,290
| New | +$767K |
|
1646
Dynavax Technologies
DVAX
$1.14B
| $758K | ﹤0.01% |
+68,024
| New | +$758K |
|
1647
SIGA Technologies
SIGA
$620M
| $757K | ﹤0.01% |
+112,197
| New | +$757K |
|
1648
Revvity
RVTY
$10B
| $751K | ﹤0.01% |
5,879
-682
| -10% | -$87.1K |
|
1649
Ambev
ABEV
$34.3B
| $750K | ﹤0.01% |
307,513
-534
| -0.2% | -$1.3K |
|
1650
Atea Pharmaceuticals
AVIR
$258M
| $742K | ﹤0.01% |
221,562
-33,604
| -13% | -$113K |
|